Affordable Medicines was Amneal Pharmaceuticals’s largest segment in fiscal 2025, bringing in $1.75B of $3.02B (58%).
| Segment | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Affordable Medicines | $1.43B | $1.47B | $1.69B | $1.75B | ||||||
| Generics | — | — | — | — | ||||||
| Avkare | $406.11M | $531.75M | $662.95M | $744.73M | ||||||
| Specialty | $374.12M | $390.46M | $445.75M | $528.51M | ||||||
| Total | $2.21B | $2.39B | $2.79B | $3.02B |
Amneal Pharmaceuticals brought in $3.02B from its three segments in fiscal 2025, the year ended December 31, 2025. That was up 8.0% from $2.79B in fiscal 2024. Affordable Medicines was the largest at $1.75B (57.8%), ahead of Avkare at $744.73M (24.7%) and Specialty at $528.51M (17.5%).
Compared with fiscal 2024, Specialty grew fastest, up 18.6% to $528.51M. Every segment above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these segments grew from $2.21B to $3.02B, a compound annual growth rate of 10.9%. Affordable Medicines' share of the total fell from 64.7% to 57.8%.
Subtotal Dosage Forms was Amneal Pharmaceuticals’s largest product and service line in fiscal 2022, bringing in $1.42B of $2.20B (65%).
| Product and Service | FY 2019 | FY 2020 | FY 2021 | FY 2022 |
|---|---|---|---|---|
| Subtotal Dosage Forms | — | — | — | $1.42B |
| Central Nervous System | $659.26M | $708.14M | $658.31M | — |
| Hormonal / Allergy | — | — | $495.47M | — |
| Hormonal/Allergy | $410.21M | $410.21M | — | — |
| Other Dosage Forms | — | — | — | $209.41M |
| Injectable | — | — | — | $188.94M |
| Distribution | — | $161.67M | $192.92M | — |
| Auto-Injector | — | — | — | $140.56M |
| Cardiovascular System | $117.07M | $114.23M | $141.87M | — |
| Transdermal | — | — | — | $119.29M |
| Government Label | — | $104.05M | $118.38M | — |
| Other Therapeutic Classes | — | $117.92M | $102.65M | — |
| Oral Liquid | — | — | — | $108.41M |
| Oncology | $62.72M | $61.11M | $103.33M | — |
| Gastroenterology | $47.01M | $78.17M | $76.50M | — |
| Dermatology | $60.19M | $58.17M | $55.47M | — |
| Metabolic Disease / Endocrine | — | — | $38.46M | — |
| Metabolic Disease/Endocrine | $56.68M | $45.00M | — | — |
| Other | $91.06M | $9.47M | $12.54M | — |
| Respiratory | $34.92M | $37.39M | $35.97M | — |
| Anti-Infective | $36.32M | $40.38M | $30.50M | — |
| Institutional | — | $18.55M | $25.18M | — |
| Antiviral | — | $25.72M | $4.83M | — |
| Antiviral (1) | $27.49M | — | — | — |
| License Agreement | — | — | — | $8.02M |
| Biosimilar | — | — | — | $3.24M |
| International | — | — | — | $1.47M |
| Total | $1.60B | $1.99B | $2.09B | $2.20B |
Amneal Pharmaceuticals brought in $2.20B from its nine product and service lines in fiscal 2022, the year ended December 31, 2022. Amneal Pharmaceuticals regrouped these lines after fiscal 2021, so the total does not compare directly with that year's $2.09B. Subtotal Dosage Forms was the largest at $1.42B (64.6%), ahead of Other Dosage Forms at $209.41M (9.5%) and Injectable at $188.94M (8.6%). The other six lines brought in $380.99M combined.
Amneal Pharmaceuticals began breaking out Subtotal Dosage Forms in fiscal 2022, Other Dosage Forms in fiscal 2022, Injectable in fiscal 2022 and Auto-Injector in fiscal 2022. Amneal Pharmaceuticals stopped reporting Central Nervous System ($658.31M in fiscal 2021), Hormonal / Allergy ($495.47M in fiscal 2021), Hormonal/Allergy ($410.21M in fiscal 2020) and 15 others as separate lines.
Us was Amneal Pharmaceuticals’s largest region in fiscal 2017, bringing in $946.60M of $1.02B (93%).
| Geography | FY 2017 |
|---|---|
| Us | $946.60M |
| International | $74.54M |
| Total | $1.02B |
Amneal Pharmaceuticals brought in $1.02B from its two regions in fiscal 2017, the year ended December 31, 2017. Us was the largest at $946.60M (92.7%), ahead of International at $74.54M (7.3%).
Amneal Pharmaceuticals (AMRX) reports its revenue by segment, by product and service and by geography. In fiscal 2025, Affordable Medicines was its largest segment, bringing in $1.75B (57.8% of the total), followed by Avkare at $744.73M (24.7%).
Affordable Medicines was Amneal Pharmaceuticals' largest segment in fiscal 2025, bringing in $1.75B, or 57.8% of the $3.02B total across its three segments.
Subtotal Dosage Forms was Amneal Pharmaceuticals' largest product and service line in fiscal 2022, bringing in $1.42B, or 64.6% of the $2.20B total across its nine product and service lines.
Us was Amneal Pharmaceuticals' largest region in fiscal 2017, bringing in $946.60M, or 92.7% of the $1.02B total across its two regions.
Among Amneal Pharmaceuticals' segments that make up at least 2% of revenue, Specialty grew fastest in fiscal 2025, up 18.6% from $445.75M to $528.51M.
Every figure comes from Amneal Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Amneal Pharmaceuticals gives it, and years follow its fiscal calendar.
Amneal Pharmaceuticals' revenue by segment goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.